Concepedia

Mitchell A. deLong

MA

14

Publications

840

Citations

13

H-Index

1990

Active since

Affiliations

Procter & Gamble (United States)(Current)

Aerie Pharmaceuticals (United States)

University of Cincinnati Medical Center

University of Alberta

Duke University

Mitchell A. deLong is an author at Procter & Gamble (United States) specializing in pharmacology, medicine, and medicinal chemistry.

Top concepts

PharmacologyMedicineBiochemistryDrug DiscoveryMedicinal ChemistryDermatologyPharmacotherapyNatural SciencesMolecular PharmacologyOsteoporosis

Publications per year

1990–2022

14

Publications

14

Discovery and Preclinical Development of Netarsudil, a Novel Ocular Hypotensive Agent for the Treatment of Glaucoma

Cheng‐Wen Lin, Bryan W. Sherman, Lori Moore et al. · Journal of Ocular Pharmacology and Therapeutics · 2017 · 181 citations · Full text

DeoxyArbutin: a novel reversible tyrosinase inhibitor with effective <i>in vivo</i> skin lightening potency

Raymond E. Boissy, Marty O. Visscher, Mitchell A. deLong · Experimental Dermatology · 2005 · 154 citations

Molecular Pharmacology, Medicinal Chemistry, Medicine +14

Discovery of the ROCK inhibitor netarsudil for the treatment of open-angle glaucoma

Jill M. Sturdivant, Susan M. Royalty, Cheng‐Wen Lin et al. · Bioorganic & Medicinal Chemistry Letters · 2016 · 104 citations · Full text

Open-angle Glaucoma, Ophthalmology, Medicine +6

Arene-alkene cycloadditions and organic synthesis

Paul A. Wender, R. J. TERNANSKY, Mitchell A. deLong et al. · Pure and Applied Chemistry · 1990 · 92 citations · Full text

Heterocyclic, Alkene Metathesis, Arene-alkene Cycloadditions +2

Mechanism of tyrosinase inhibition by deoxyArbutin and its second-generation derivatives

Smita Chawla, Mitchell A. deLong, Marty O. Visscher et al. · British Journal of Dermatology · 2008 · 67 citations

Rows per page

1–5 of 14